Prosecution Insights
Prosecution Insights
16 pending office actions • 8 art units • 15 examiners • 0 of 16 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (19%) |
| §112 only | 6 (38%) |
| Double-patenting + other | 2 (12%) |
| Multi-statute (no §101) | 5 (31%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FETTEROLF, BRANDON J | 2 | 51.4% | +17.1% |
| PURDY, KYLE A | 1 | 41.0% | +36.5% |
| TAO, BIN | 1 | 100.0% | +0.0% |
| BAKSHI, PANCHAM | 1 | 77.0% | +30.2% |
| JOHANNSEN, DIANA B | 1 | 53.3% | +42.5% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.3% | +20.3% |
| FERGUSON, JALISA HOLMES | 1 | 61.8% | +56.5% |
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 61.9% | +40.0% |
| RODRIGUEZ, RAYNA B | 1 | 33.1% | +20.0% |
| HERNANDEZ, JACKSON J | 1 | 50.9% | +28.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17788847 | AGENT FOR ADJUVANT THERAPY | KONOPELSKI SNAVEL, SARA ELIZABETH | 88d overdue |
| 18563058 | TREATMENT METHODS FOR SUBJECTS WITH CANCER HAVING AN ABERRATION IN EGFR AND/OR HER2 | FETTEROLF, BRANDON J | 9d |
| 16627146 | CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND | MCKOY, QUINCY ANDRE | 22d |
| 18026515 | METHODS OF TREATING RIBONUCLEOTIDE REDUCTASE-RELATED DISEASES WITH A RIBONUCLEOTIDE REDUCTASE INHIBITOR | RODRIGUEZ, RAYNA B | 23d |
| 18549249 | TREATING CANCER IN PATIENT HAVING CO-OCCURRING GENETIC ALTERATION IN FGFR2 AND A CANCER DRIVER GENE | WHITE, DAWANNA SHAR-DAY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18015616 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | HERNANDEZ, JACKSON J | 238d overdue |
| 18563058 | TREATMENT METHODS FOR SUBJECTS WITH CANCER HAVING AN ABERRATION IN EGFR AND/OR HER2 | FETTEROLF, BRANDON J | 9d |
| 18253521 | Crystalline Forms of 4-amino-N-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide, Methods of Preparation, and uses Thereof | FETTEROLF, BRANDON J | 15d |
| 18026515 | METHODS OF TREATING RIBONUCLEOTIDE REDUCTASE-RELATED DISEASES WITH A RIBONUCLEOTIDE REDUCTASE INHIBITOR | RODRIGUEZ, RAYNA B | 23d |
| 18253273 | BRAIN-MIGRATING TUMOR THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | FERGUSON, JALISA HOLMES | 75d |
| 18873090 | PHARMACEUTICAL COMPOSITION CONTAINING PIMITESPIB | PURDY, KYLE A | — |
| 18422511 | COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER | BAKSHI, PANCHAM | — |
| 18512528 | SELECTIVE INHIBITOR OF EXON 20 INSERTION MUTANT EGFR | JOHANNSEN, DIANA B | — |
| Art Unit | Apps |
|---|---|
| 1626 | 5 |
| 1627 | 2 |
| 1628 | 2 |
| 1623 | 1 |
| 1682 | 1 |
| 1629 | 1 |
| 1658 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18873090 | PHARMACEUTICAL COMPOSITION CONTAINING PIMITESPIB | PURDY, KYLE A | — | §103 | Non-Final OA | — | Pending | Dec 09, 2024 |
| 18704901 | PROCESS FOR PREPARING A BENZOATE SALT OF A 1-(3-AMINOPYRROLIDINE-1-CARBONYL)-3,4-DIPHENYLBENZENE COMPOUND | TAO, BIN | — | §103 | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18422511 | COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER | BAKSHI, PANCHAM | 1623 | §112 | Non-Final OA | — | Pending | Jan 25, 2024 |
| 18563058 | TREATMENT METHODS FOR SUBJECTS WITH CANCER HAVING AN ABERRATION IN EGFR AND/OR HER2 | FETTEROLF, BRANDON J | 1626 | §102§103Other | Non-Final OA | 9d | Pending | Nov 21, 2023 |
| 18512528 | SELECTIVE INHIBITOR OF EXON 20 INSERTION MUTANT EGFR | JOHANNSEN, DIANA B | 1682 | §112Other | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18549249 | TREATING CANCER IN PATIENT HAVING CO-OCCURRING GENETIC ALTERATION IN FGFR2 AND A CANCER DRIVER GENE | WHITE, DAWANNA SHAR-DAY | 1627 | §102§103Other | Non-Final OA | — | Pending | Sep 06, 2023 |
| 18253521 | Crystalline Forms of 4-amino-N-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide, Methods of Preparation, and uses Thereof | FETTEROLF, BRANDON J | 1626 | §112 | Non-Final OA | 15d | Pending | May 18, 2023 |
| 18253273 | BRAIN-MIGRATING TUMOR THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | FERGUSON, JALISA HOLMES | 1626 | §103DPOther | Final Rejection | 75d | Pending | May 17, 2023 |
| 18253229 | Methods of Using 4-Amino-N-[4-(Methoxymethyl)Phenyl]-7-(1-Methylcyclopropyl)-6-(3-Morpholinoprop-1-YN-1-YL)-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carboxamide for the Treatment of Tumors | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §102DPOther | Final Rejection | — | Pending | May 17, 2023 |
| 18026515 | METHODS OF TREATING RIBONUCLEOTIDE REDUCTASE-RELATED DISEASES WITH A RIBONUCLEOTIDE REDUCTASE INHIBITOR | RODRIGUEZ, RAYNA B | 1628 | §103§112Other | Final Rejection | 23d | Pending | Mar 15, 2023 |
| 18015616 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | HERNANDEZ, JACKSON J | 1627 | §112Other | Non-Final OA | 238d overdue | Pending | Jan 11, 2023 |
| 17917765 | CANCER THERAPY USING 3,5-DISUBSTITUTED BENZENE ALKYNYL COMPOUND AND MEK INHIBITOR | HAVLIN, ROBERT H | 1626 | §103Other | Final Rejection | 10d overdue | Pending | Oct 07, 2022 |
| 17788847 | AGENT FOR ADJUVANT THERAPY | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §102§103§112Other | Non-Final OA | 88d overdue | Pending | Jun 24, 2022 |
| 17786504 | THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | WILLIS, DOUGLAS M | 1624 | §112 | Non-Final OA | 3d overdue | Pending | Jun 16, 2022 |
| 17432158 | PHARMACEUTICAL COMPOSITION AND THERAPEUTIC METHOD FOR TREATING FGFR1 VARIANT-POSITIVE BRAIN TUMOR | COPPINS, JANET L | 1628 | §112 | Final Rejection | — | Pending | Aug 19, 2021 |
| 16627146 | CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND | MCKOY, QUINCY ANDRE | 1626 | §103§112Other | Final Rejection | 22d | Pending | Dec 27, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial